XML 68 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 12 Months Ended
May 10, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 20, 2018
Shares issued   17,544,509 13,485,128  
Accrued interest   $ 1,019,889 $ 742,374  
Revenue   56,239,667 55,406,337  
Grigorios Siokas Three [Member]        
Borrowing   2,040,635    
Outstanding principal balance   1,293,472 1,629,246  
Additional proceeds from debt   275,306    
Repayment of loans   133,552    
Foreign curreny translation   $ 20,623 27,114  
Debt instrument conversion price   $ 6.00    
Convertible share description   Mr. Siokas whereby the Company exchanged an aggregate total of $6,000,000 of debt into 1,000,000 shares of Common Stock at above market prices.    
Debt instrument converted amount   $ 2,250,000    
Shares issued   375,000    
Grigorios Siokas [Member]        
Borrowing       $ 1,718,400
Outstanding principal balance   $ 452,720 489,200  
Accrued interest   200,683 193,585  
Interest rate       4.70%
Maturity date       Mar. 18, 2019
Litigation settlement $ 600,000      
Plantiff attorney fees 120,000      
Litigation cost $ 4,137      
Dimitrios Goulielmos [Member]        
Outstanding principal balance   11,544 12,475  
DOC Pharma S.A. [Member]        
Foreign curreny translation   37,411 122,279  
Payments to purchase products   3,084,805 5,983,809  
Accounts payable balance   565,756    
Accounts receivable balance   2,901,300 3,468,653  
Prepaid balance   3,263,241 3,468,564  
Revenue   $ 978,321 $ 2,843,260  
Agreement term   5 years    
Pieces per product   1,000 pieces    
Inventroy purchase   $ 2,010,517    
Description of research and development   Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). In the year ended December 31, 2021, SkyPharm bought 67 licenses at value of €261,300 ($295,739) from Doc Pharma which was the 18.33% of the total cost. The agreement will be terminated on December 31, 2025